Literature DB >> 1456572

Inhibition by L-NG-nitro-L-arginine of nonadrenergic-noncholinergic-mediated relaxations of human isolated central and peripheral airway.

J L Ellis1, B J Undem.   

Abstract

Human isolated central (5 to 12 mm) and peripheral (< 2 mm) bronchi were contracted with 3 microM histamine. Relaxations were then evoked by electrical field stimulation (EFS) (1 to 32 Hz, 1 ms, 12 V for 15 s in the presence of indomethacin, atropine, and propranolol). The magnitude, time-course, and frequency-response relationship of these nonadrenergic, noncholinergic (NANC) relaxations were similar in the central and the peripheral airways. NG-Nitro-L-arginine (L-NOARG) (10 microM) inhibited the tetrodotoxin-sensitive NANC relaxations in both central and peripheral bronchi, whereas the stereoisomer D-NOARG was without effect. This inhibition was reversed by L-arginine (1 mM) but not be D-arginine (1 mM). The nitric oxide donor compound, 3-morpholinosydnonimine (SIN-1), was equipotent at relaxing the central and peripheral airways. Vasoactive intestinal peptide (VIP), although it relaxed central airways, was virtually ineffective in relaxing the peripheral airways. In addition, the peptidase, alpha-chymotrypsin, at a concentration that blocked relaxations to VIP, was without effect on NANC relaxations in the central bronchi. The results support the following hypotheses: (1) both central and peripheral airways receive nonadrenergic relaxant innervation; (2) the relaxant response to electrical stimulation of this system is dependent on a pathway involving L-arginine; and (3) the relaxant response does not appear to involve VIP, but it may involve the production of nitric oxide.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1456572     DOI: 10.1164/ajrccm/146.6.1543

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  13 in total

Review 1.  NO as a signalling molecule in the nervous system.

Authors:  Juan V Esplugues
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

Review 2.  Nitric oxide and lung disease.

Authors:  P J Barnes; M G Belvisi
Journal:  Thorax       Date:  1993-10       Impact factor: 9.139

3.  Antiasthmatic activity of quercetin glycosides in neonatal asthmatic rats.

Authors:  Suyue Zhu; Haijun Wang; Jun Zhang; Chunlin Yu; Chengquan Liu; Haiping Sun; Yunduo Wu; Yumei Wang; Xiaofei Lin
Journal:  3 Biotech       Date:  2019-04-26       Impact factor: 2.406

Review 4.  Arginase: a key enzyme in the pathophysiology of allergic asthma opening novel therapeutic perspectives.

Authors:  Harm Maarsingh; Johan Zaagsma; Herman Meurs
Journal:  Br J Pharmacol       Date:  2009-08-24       Impact factor: 8.739

5.  Phosphodiesterase V inhibition reduces airway responsiveness, but does not improve the beneficial effect of deep inspiration.

Authors:  George Pyrgos; Alkis Togias; Robert H Brown
Journal:  Respiration       Date:  2013-07-16       Impact factor: 3.580

Review 6.  Multiple roles of nitric oxide in the airways.

Authors:  F L M Ricciardolo
Journal:  Thorax       Date:  2003-02       Impact factor: 9.139

7.  Regional difference in the distribution of L-NAME-sensitive and -insensitive NANC relaxations in cat airway.

Authors:  N Takahashi; H Tanaka; N Abdullah; L Jing; R Inoue; Y Ito
Journal:  J Physiol       Date:  1995-11-01       Impact factor: 5.182

Review 8.  Using guinea pigs in studies relevant to asthma and COPD.

Authors:  Brendan J Canning; Yangling Chou
Journal:  Pulm Pharmacol Ther       Date:  2008-02-02       Impact factor: 3.410

9.  Role of nitric oxide in non-adrenergic, non-cholinergic relaxation and modulation of excitatory neuroeffector transmission in the cat airway.

Authors:  L Jing; R Inoue; K Tashiro; S Takahashi; Y Ito
Journal:  J Physiol       Date:  1995-02-15       Impact factor: 5.182

10.  Low voltage vagal nerve stimulation reduces bronchoconstriction in guinea pigs through catecholamine release.

Authors:  Thomas J Hoffmann; Bruce J Simon; Yi Zhang; Charles W Emala
Journal:  Neuromodulation       Date:  2012-05-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.